One of the promising strategies involves the use of EVs inhibitors, such as GW4869, which have shown potential in modulating the immunosuppressive tumor microenvironment (166).Furthermore, small interfering RNAs (siRNAs) targeting RAB27A or nSMase2—key enzymes in extracellular vesicle (EV) biogenesis—further validate this strategy. Here, SMPD3 is linked to neoplasm.